Why the study?
Does low-dose candesartan improve re-endothelialisation following vascular wound healing in a rabbit model of aortic injury?
Does low-dose candesartan improve re-endothelialisation following vascular wound healing in a rabbit model of aortic injury?
Low-dose candesartan significantly increases the rate of re-endothelialisation following vascular injury in a rabbit model, suggesting pleiotropic effects on vascular wound healing.
No immediate clinical implications for vascular repair; leaves open dose-specific ARB effects on endothelial healing in humans.
The wound healing response of the vascular wall to injury involves re-endothelialisation of the denuded luminal surface and thickening of the intimal area (intimal hyperplasia), as expressed by the intimal-to-medial area ratio (I/M). Candesartan, at doses of 1 mg/kg/day or higher, has been reported to attenuate the intimal hyperplastic response. We tested the hypothesis that candesartan, at doses lower than those associated with attenuation of intimal hyperplasia, may affect re-endothelialisation. New Zealand White rabbits were subjected to balloon catheter injury to the thoracic aorta. Candesartan, at doses of 50, 100, and 500 µg/kg/day, was delivered via an Alzet pump placed in the abdomen one week prior to aortic injury. There was no attenuation of the hyperplastic response of the aortic wall. However, at 50 µg/kg/day the rate of reendothelialisation was significantly increased. These data suggest that candesartan may exhibit pleiotropic effects on vascular wound healing, in addition to the well-known effect of attenuating the development of intimal hyperplasia.
No takes yet. Share an insight, caveat, or question.
Koshy et al. (2001) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: